Author + information
- Nicolas W. Shammas1,
- Gail Shammas1,
- Sue Jones-Miller1,
- Bassel Bou Dargham1,
- Andrew Shammas2,
- Subhash Banerjee3,
- Rayan Jo Rachwan1,
- Ghassan Daher1 and
- W John Shammas1
The long-term outcome of Jetstream atherectomy (JA) with or without adjunctive drug coated balloons (DCB) in a real-world setting remains unknown. We report 18-month target lesion revascularization (TLR) rates on patients treated for denovo femoropopliteal (FP) artery disease with JA in a single center by one operator.
From 1/1/12 to 8/24/16 311 procedures were performed with atherectomy by a single operator at a single center. 77 procedures were excluded because they were performed with a non JA device or were infra-popliteal. The remaining procedures (n=234) were performed in 81 patients (81 JA at index, 153 atherectomy procedures on follow-up). Of the 81 JA at index, adjunctive balloon angioplasty (PTA) was performed on 26 denovo lesions and adjunctive DCB on 23 denovo lesions (LUTONIX® 22, IN.PACT® 1). This report evaluates the 18-month outcome of the 49 patients with denovo disease. The primary endpoint of the study was clinically driven target lesion revascularization (TLR). Survival analysis for TLR over time was plotted.
There was no difference in the mean treated length between the adjunctive PTA (14.9 ± 9.3 cm) and DCB (12.0 ± 6.6 cm) groups (p=0.1). The TLR rate was significantly reduced with atherectomy and adjunctive DCB compared to atherectomy with adjunctive PTA at 18 months (proportional rates: 94% vs 50% respectively; p=0.0006). (figure)
In a single center cohort of JA reflecting real-world practice, JA with DCB had a superior TLR rate at 18 months follow-up when compared to JA with PTA in treating denovo femoropopliteal disease.
CORONARY: Drug-Eluting Balloons and Local Drug Delivery